Reshaping the HIV treatment and prevention landscape
Unique pipeline targeting CD226 axis: TIGIT^, CD96,
PVRIG with potential for synergistic anti-tumour effect
Interaction between tumours and immune
system point towards new combinations...
Example: T/NK cell interacting with tumours
gsk
...testing these combinations shows promising
synergies in pharmacology studies
Example: PD1 + TIGIT + CD96 in colon carcinoma (CT26) cells
PD-10
Dostarlimab
(Anti-PD-1 mAb)
CD96
+CD226
TIGIT
PVRIG
GSK608
(Anti-CD96 mAb)
EOS448
T/NK cell
(Anti-TIGIT mAb)
GSK652
(Anti-PVRIG mAb)
PD-L1
CD155
8
BCD112
CD96, TIGIT, and PVRIG
are checkpoint inhibitors
APC/Tumor
Mean tumor size (mm2)
200
<- cig
aCD96
αPD1
AaTIGIT (G2a).
****
aCD96 + aTIGIT (G2a)
aPD1+aCD96
aPD1+aTIGIT (G2a)
aPD1+aTIGIT (G2a)+ CD96
150-
100
50-
0
0
5 10 15 20 25 30 35 40 45 50 55
Days after CT26 tumor inoculation
Note: PD1 + TIGIT + CD96 synergistic effect adapted from Mittal et al. Control = anti-CLG antibodies.
Source: GSK internal data; Mittal et al. Cancer Immunol Res. 2019
^iTeos Therapeutics collaboration subject to regulatory clearance
Source: Mittal et al. 2019 CRI
Triplet
93View entire presentation